David R. Tawil
David is a litigation associate at Seeger Weiss LLP, where he has practiced since 2013. He handles a wide variety of matters, focusing on product liability, pharmaceutical injury, and automobile defect cases. David has worked with dozens of expert witnesses and has developed a keen understanding of epidemiology, statistics, and pharmacology while pursuing mass tort cases against some of the largest companies in the world on behalf of injured consumers. In 2020 and 2021, David was selected to the Super Lawyers – Rising Stars list for the New York Metro area,* as well as Best Lawyers: Ones to Watch.** In addition, he participates as a Barrister of the John C. Lifland American Inn of Court.
Prior to joining the Firm, David served as a Civil and Multicounty Litigation law clerk to the Hon. Jessica R. Mayer, in Middlesex County, New Jersey, which sparked his interest in complex litigation. Before that, he interned for the Hon. Fredericka H. Wicker at the Fifth Circuit Court of Appeal in Gretna, Louisiana, while at Tulane Law School.
*The Super Lawyers – Rising Stars list is issued by Thomson Reuters, and a description of the selection methodology can be found here. No aspect of this advertisement has been approved by the Supreme Court of New Jersey.
**The Best Lawyers: Ones to Watch list is issued by Best Lawyers, and a description of the selection methodology can be found here. No aspect of this advertisement has been approved by the Supreme Court of New Jersey.
- New York
- New Jersey
David regularly represents injured consumers in federal and state courts around the country, including:
- Key member of litigation and briefing teams in various matters, including In re National Prescription Opiate Litigation in the Northern District of Ohio; In re Zantac (Ranitidine) Products Liability Litigation in the Southern District of Florida; In re Proton-Pump Inhibitor Products Liability Litigation in the District of New Jersey; In re Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation in the Eastern District of Pennsylvania (and parallel state court litigation in New Jersey); and In re Fresenius Granuflo/Naturalyte Dialysate Products Liability Litigationin the District of Massachusetts.
- Various “Clean Diesel” emissions matters, beginning with In re Volkswagen “Clean Diesel” Marketing, Sales Practices, and Products Liability Litigation, where he represented plaintiffs in historic class action against Volkswagen and Bosch that resulted in $14.7 billion settlement. Today, David continues to represent aggrieved plaintiffs in similar matters, including in In re Mercedes-Benz Emissions Litig. and Rickman et al. v. BMW, both centralized in the District of New Jersey; and in Counts et al. v. General Motors, LLC, Fenner et al. v. General Motors, LLC, Gamboa et al. v. Ford Motor Co., and Bledsoe et al. v. FCA US LLC, all centralized in the Eastern District of Michigan.
- In re Testosterone Replacement Therapy (“TRT”) Products Liability Litigation, where he represented plaintiffs in consolidated multi-district litigation in the Northern District of Illinois, pursuing claims for cardiovascular injuries as a result of using TRT products. David was a key member of the trial teams representing Oregon and Tennessee plaintiffs in the first two federal bellwether trials against AbbVie, in which juries awarded close to $300 million in combined damages on claims of negligence and fraud relating to AndroGel® safety and marketing. His involvement included assisting lead trial counsel in preparation for opening statements, closing arguments, and examinations of multiple plaintiff and defense expert witnesses.
- In re Proton-Pump Inhibitor Prods. Liab. Litig., MDL No. 2789 (D.N.J.) Member of the Seeger Weiss team representing a consolidated multidistrict litigation of about 195 federal lawsuits against pharmaceutical giants Pfizer Inc., AstraZeneca Pharmaceuticals LP, Novartis Consumer Health Inc., Proctor & Gamble Co. and Takeda Pharmaceutical Co. Ltd., alleging that their proton pump inhibitor (PPI) drugs—which more than 15 million Americans use—cause serious kidney injury.
- In re Accutane Litigation, where he is the primary associate on trial and appellate teams in New Jersey state court, with various accomplishments including:
- Convincing NJ Supreme Court to adopt Section 142 of the Restatement (Second) of Conflicts of Law, resulting in reinstatement of $25 million verdict for Alabama plaintiff (McCarrell v. Hoffmann-La Roche, Inc., 227 N.J. 569, 153 A.3d 207 (2017))
- Convincing NJ Appellate Division to reverse trial court ruling involving expert admissibility, resulting in reinstatement of over 2,000 cases (In re Accutane Litig., 451 N.J. Super. 153, 165 A.3d 832 (App. Div. 2017))
- Convincing NJ Appellate Division to reverse trial court ruling regarding choice of law and adequacy of the Accutane® label, resulting in the reinstatement of over 300 cases (In re Accutane Litig., No. A-0164-15T1, 2017 WL 3138003) (N.J. Super. Ct. App. Div. July 25, 2017))
*Prior results do not guarantee or predict a similar outcome in any future matter.
Publications & Presentations
Publications & Presentations
Note: Kiobel v. Royal Dutch Petroleum Co.: The Second Circuit Rejects Corporate Liability Under the Alien Tort Statute (19 Tul. J. Int’l & Comp. L. 709)
Implications of PLIVA, Inc. v. Mensing: The Reemergence of Federal Preemption (unpublished)